Publicaciones en colaboración con investigadores/as de Instituto Cajal (20)

2024

  1. The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls

    EMBO Molecular Medicine, Vol. 16, Núm. 4, pp. 755-783

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

    Neurobiology of Disease, Vol. 141

  2. Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure

    Neuropsychopharmacology, Vol. 45, Núm. 5, pp. 877-886

2018

  1. The APPswe/PS1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca 2+ dysregulation, and mitochondrial abnormalities

    Journal of Neurochemistry, Vol. 145, Núm. 2, pp. 170-182

2016

  1. Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis

    Journal of Medicinal Chemistry, Vol. 59, Núm. 14, pp. 6753-6771

2015

  1. A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis

    British Journal of Pharmacology, Vol. 172, Núm. 14, pp. 3579-3595

2012

  1. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis

    Journal of Neuroimmune Pharmacology, Vol. 7, Núm. 4, pp. 1002-1016

  2. Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases

    Neuroscience Letters, Vol. 508, Núm. 2, pp. 67-72

2011

  1. Prospects for cannabinoid therapies in basal ganglia disorders

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378

2005

  1. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

    Neurobiology of Disease, Vol. 20, Núm. 2, pp. 207-217

  2. Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation

    Journal of Neuroscience, Vol. 25, Núm. 8, pp. 1904-1913

  3. The role of cannabinoids in preventing the neurodegenerative process occurring in Alzheimer's disease

    Drugs of the Future, Vol. 30, Núm. 8, pp. 807-814

2002

  1. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats

    Developmental Brain Research, Vol. 136, Núm. 2, pp. 85-92

  2. Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity

    Journal of Neurochemistry, Vol. 82, Núm. 1, pp. 154-158

  3. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway

    Journal of Biological Chemistry, Vol. 277, Núm. 39, pp. 36527-36533

2001

  1. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets

    European Journal of Neuroscience, Vol. 14, Núm. 11, pp. 1827-1832

  2. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor

    Cancer Research, Vol. 61, Núm. 15, pp. 5784-5789

1999

  1. The AMP-activated protein kinase is involved in the regulation of ketone body production by astrocytes

    Journal of Neurochemistry, Vol. 73, Núm. 4, pp. 1674-1682

1998

  1. Central olfactory structures in Pax-6 mutant mice

    Annals of the New York Academy of Sciences